425: Carisma Therapeutics Faces Renewed Nasdaq Delisting Threat, Proposes Reverse Stock Split Amid Compliance Struggles

Carisma Therapeutics Inc. received an additional delisting notice from Nasdaq for failing to meet the minimum bid price requirement and plans a reverse stock split to regain compliance while also pursuing a merger with OrthoCellix, Inc.

Summary

• Carisma Therapeutics Inc. (CARM) was notified by Nasdaq on July 9, 2025, that its failure to timely regain compliance with the minimum bid price rule ($1.00 per share) could serve as an additional basis for delisting.
• The company had previously been notified on January 6, 2025, of non-compliance with the Nasdaq Global Market (NGM) Bid Price Rule and was granted a 180-calendar day grace period, which expired on July 7, 2025, without compliance being met.
• Carisma's securities were already subject to delisting from NGM due to non-compliance with market value of publicly held shares and market value of listed securities requirements.
• Following a hearing, the Nasdaq Hearings Panel granted the company's request to transfer its listing to The Nasdaq Capital Market (NCM), effective June 12, 2025.
• The Panel provided an exception, allowing Carisma until October 7, 2025, to demonstrate compliance with all NCM listing criteria, including the applicable bid price requirement.
• A special meeting of stockholders is scheduled for August 5, 2025, to approve an amendment to the certificate of incorporation to effect a reverse stock split at a ratio of not less than 1-for-10 and not greater than 1-for-50 shares.
• The primary purpose of the reverse stock split is to increase the per-share closing bid price to meet the NCM Bid Price Rule and help ensure continued Nasdaq listing.
• There is no assurance that the reverse stock split, if effected, will enable the company to demonstrate compliance or satisfy the terms of the Panel's decision by October 7, 2025.
• The document also references a proposed merger involving Carisma and OrthoCellix, Inc.

Sentiment

Score: 3

Explanation: The company is facing significant listing compliance issues, having failed to meet multiple Nasdaq requirements and receiving an additional delisting notice. While a plan (reverse stock split) is in place, its success is explicitly stated as uncertain, indicating high risk and negative sentiment regarding its immediate operational and financial stability as a publicly traded entity.

Positives

• Nasdaq granted a transfer of listing to The Nasdaq Capital Market (NCM), providing a pathway for continued listing.
• The company has until October 7, 2025, to evidence compliance with NCM listing criteria, including the bid price rule.
• Carisma is actively pursuing a corporate action (reverse stock split) to address the bid price deficiency and maintain its Nasdaq listing.

Negatives

• Carisma Therapeutics failed to timely regain compliance with Nasdaq's minimum bid price rule by the July 7, 2025 deadline.
• Nasdaq issued an additional delisting notice on July 9, 2025, citing the continued bid price deficiency as a potential basis for delisting.
• The company was already non-compliant with Nasdaq's market value of publicly held shares and market value of listed securities requirements.
• There is no assurance that the proposed reverse stock split will enable the company to demonstrate compliance or satisfy the terms of the Panel's decision by October 7, 2025.

Risks

• Failure to regain compliance with Nasdaq's minimum bid price rule (NCM Bid Price Rule) by October 7, 2025, could result in the delisting of the company's securities.
• The proposed reverse stock split may not be sufficient to increase the stock price to the required level or maintain it above that level.
• Stockholder approval for the reverse stock split is required, and there is no guarantee it will be obtained.
• The company's ability to satisfy the terms of the Nasdaq Hearings Panel's decision by the October 7, 2025 deadline is uncertain.
• Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from expectations, including meeting Nasdaq compliance standards and other listing requirements.

Future Outlook

Carisma Therapeutics aims to regain compliance with Nasdaq's listing requirements, specifically the NCM Bid Price Rule, by October 7, 2025, through a proposed reverse stock split. However, there is no assurance that these actions will be successful in ensuring continued listing on Nasdaq. The company also mentions a proposed merger with OrthoCellix, Inc.

Management Comments

• There can be no assurance that the company will achieve such expectations, including meeting Nasdaq compliance standards and other Nasdaq requirements and conditions for listing.

Industry Context

This announcement highlights the ongoing challenges faced by smaller biotechnology or early-stage companies in maintaining Nasdaq listing compliance, particularly regarding minimum bid price and market capitalization requirements. Such companies often rely on capital markets for funding and visibility, making continued listing crucial. The proposed reverse stock split is a common strategy employed by companies to avoid delisting when their stock price falls below minimum thresholds, a situation frequently observed in volatile or challenging market conditions for development-stage firms. The mention of a merger suggests potential strategic consolidation or a pivot for the company.

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential dilution from a reverse stock split (in terms of number of shares held, though not percentage ownership), risk of delisting if compliance is not met, and uncertainty regarding the company's future listing status. Voting on the reverse stock split is required.
• Employees: No direct impact mentioned, but delisting could affect company morale, stock options, and future stability.
• Customers/Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Hold a special meeting of stockholders on August 5, 2025, to approve an amendment to the certificate of incorporation for a reverse stock split.
• The Board of Directors will determine the exact ratio of the reverse stock split (between 1-for-10 and 1-for-50 shares).
• Evidence compliance with all applicable criteria for listing on The Nasdaq Capital Market (NCM), including the bid price requirement, by October 7, 2025.
• File relevant materials with the SEC regarding the proposed merger with OrthoCellix, Inc., including a registration statement on Form S-4.

Key Dates

Recommendation

Keywords

Carisma Therapeutics, CARM, Nasdaq, Delisting, Reverse Stock Split, Stock Price Compliance, Nasdaq Capital Market, SEC Filing, Corporate Governance, OrthoCellix, Merger